Format
Items per page
Sort by

Send to:

Choose Destination

Results: 20

Related Articles by Review for PubMed (Select 17613529)

1.

Modulation of serpin reaction through stabilization of transient intermediate by ligands bound to alpha-helix F.

Komissarov AA, Zhou A, Declerck PJ.

J Biol Chem. 2007 Sep 7;282(36):26306-15. Epub 2007 Jul 5.

2.

Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin (Vn): mapping the binding sites on PAI-1 and Vn.

Schroeck F, Arroyo de Prada N, Sperl S, Schmitt M, Viktor M.

Biol Chem. 2002 Jul-Aug;383(7-8):1143-9. Review.

PMID:
12437099
4.

Structure-function relationships of plasminogen activator inhibitor-1 and its potential as a therapeutic agent.

Cale JM, Lawrence DA.

Curr Drug Targets. 2007 Sep;8(9):971-81. Review.

PMID:
17896949
5.

The story of the serpin plasminogen activator inhibitor 1: is there any need for another mutant?

De Taeye B, Gils A, Declerck PJ.

Thromb Haemost. 2004 Nov;92(5):898-924. Review.

PMID:
15543316
7.

Biochemical properties of plasminogen activator inhibitor-1.

Dupont DM, Madsen JB, Kristensen T, Bodker JS, Blouse GE, Wind T, Andreasen PA.

Front Biosci (Landmark Ed). 2009 Jan 1;14:1337-61. Review.

8.

Serpins, the vasculature, and viral therapeutics.

Richardson J, Viswanathan K, Lucas A.

Front Biosci. 2006 Jan 1;11:1042-56. Review.

PMID:
16146796
10.

The undecided serpin. The ins and outs of plasminogen activator inhibitor type 2.

Medcalf RL, Stasinopoulos SJ.

FEBS J. 2005 Oct;272(19):4858-67. Review.

11.

Divining the serpin inhibition mechanism: a suicide substrate 'springe'?

Engh RA, Huber R, Bode W, Schulze AJ.

Trends Biotechnol. 1995 Dec;13(12):503-10. Review.

PMID:
8595135
12.

New functions for an old enzyme: nonhemostatic roles for tissue-type plasminogen activator in the central nervous system.

Yepes M, Lawrence DA.

Exp Biol Med (Maywood). 2004 Dec;229(11):1097-104. Review.

PMID:
15564435
13.

Tissue-type plasminogen activator and neuroserpin: a well-balanced act in the nervous system?

Yepes M, Lawrence DA.

Trends Cardiovasc Med. 2004 Jul;14(5):173-80. Review.

PMID:
15261888
14.

Plasminogen activator inhibitor-1 in vascular thrombosis.

Westrick RJ, Eitzman DT.

Curr Drug Targets. 2007 Sep;8(9):966-1002. Review.

PMID:
17896948
15.

Targeting plasminogen activator inhibitor-1: role in cell signaling and the biology of domain-specific knock-in mice.

Balsara RD, Xu Z, Ploplis VA.

Curr Drug Targets. 2007 Sep;8(9):982-95. Review.

PMID:
17896950
16.

Genetic architecture of tissue-type plasminogen activator and plasminogen activator inhibitor-1.

Asselbergs FW, Pattin K, Snieder H, Hillege HL, van Gilst WH, Moore JH.

Semin Thromb Hemost. 2008 Sep;34(6):562-8. doi: 10.1055/s-0028-1103367. Epub 2008 Nov 28. Review.

PMID:
19085655
17.

Fibrinolysis: the key to new pathogenetic mechanisms.

Zorio E, Gilabert-Estellés J, España F, Ramón LA, Cosín R, Estellés A.

Curr Med Chem. 2008;15(9):923-9. Review.

PMID:
18473800
18.

Anti-apoptotic roles of plasminogen activator inhibitor-1 as a neurotrophic factor in the central nervous system.

Soeda S, Koyanagi S, Kuramoto Y, Kimura M, Oda M, Kozako T, Hayashida S, Shimeno H.

Thromb Haemost. 2008 Dec;100(6):1014-20. Review.

PMID:
19132224
19.

An overview of the serpin superfamily.

Law RH, Zhang Q, McGowan S, Buckle AM, Silverman GA, Wong W, Rosado CJ, Langendorf CG, Pike RN, Bird PI, Whisstock JC.

Genome Biol. 2006;7(5):216. Epub 2006 May 30. Review.

20.

Plant serine proteinase inhibitors.

Christeller J, Laing W.

Protein Pept Lett. 2005 Jul;12(5):439-47. Review.

PMID:
16029156
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk